Amato R - Search Results

1

Phase I trial of a 72-h continuous-infusion schedule of fazarabine.

Amato R, Ho D, Schmidt S, Krakoff IH, Raber M. Amato R, et al. Cancer Chemother Pharmacol. 1992;30(4):321-4. doi: 10.1007/BF00686303. Cancer Chemother Pharmacol. 1992. PMID: 1379523 Clinical Trial.

2

Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.

Abbruzzese JL, Amato R, Schmidt S, Raber MN, Frost P. Abbruzzese JL, et al. Among authors: amato r. Cancer Chemother Pharmacol. 1990;26(3):159-62. doi: 10.1007/BF02897192. Cancer Chemother Pharmacol. 1990. PMID: 2357761

3

Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion.

Ho DH, Brown N, Lin JR, Covington W, Newman RA, Raber M, Amato R, Schmidt S, Krakoff IH. Ho DH, et al. Among authors: amato r. Drug Metab Dispos. 1991 May-Jun;19(3):643-7. Drug Metab Dispos. 1991. PMID: 1717216

4

Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.

Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ. Ellerhorst JA, et al. Among authors: amato rj. Cancer. 1997 Dec 1;80(11):2128-32. Cancer. 1997. PMID: 9392335 Clinical Trial.

5

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma.

Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. Pagliaro L, et al. Among authors: amato r. Cancer. 2000 Aug 1;89(3):615-8. Cancer. 2000. PMID: 10931461 Clinical Trial.

6

A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.

Amato RJ, Khan M. Amato RJ, et al. Cancer Chemother Pharmacol. 2008 May;61(6):1069-73. doi: 10.1007/s00280-007-0568-7. Epub 2007 Aug 14. Cancer Chemother Pharmacol. 2008. PMID: 17701037 Clinical Trial.

7

A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Amato R, Stepankiw M, Gonzales P. Amato R, et al. Cancer Chemother Pharmacol. 2013 Jun;71(6):1629-34. doi: 10.1007/s00280-013-2163-4. Epub 2013 Apr 21. Cancer Chemother Pharmacol. 2013. PMID: 23604530 Clinical Trial.

8

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.

Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R. Chiorean EG, et al. Among authors: amato r. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. doi: 10.1007/s00280-014-2389-9. Epub 2014 Jan 23. Cancer Chemother Pharmacol. 2014. PMID: 24452395 Clinical Trial.

9

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.

Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R. Daliani DD, et al. Among authors: amato r. Cancer. 2002 Aug 15;95(4):758-65. doi: 10.1002/cncr.10740. Cancer. 2002. PMID: 12209719 Free article. Clinical Trial.

10

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.

Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. Amato RJ, et al. Cancer. 2009 Jun 1;115(11):2438-46. doi: 10.1002/cncr.24280. Cancer. 2009. PMID: 19306412 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

746 results

Search Page

Filters